- Sher, I., Zisman-Rozen, S., Eliahu, L., Whitelock, J.M., Maas-Szabowski, N., Yamada, Y., Breitkreutz, D.,. Fusenig, N.E., Arikawa-Hirasawa, E., Iozzo, R.V., Bergman, R. and Ron, D. (2006) Targeting perlecan in human keratinocytes reveals novel roles for perlecan in epidermis formation. J Biol. Chem. 28, 5178-87. (Cited in the Faculty of 1000).
- Zisman-Rozen, S., Fink, D., Ben-Izhak, O., Fuchs, Y., Brodski, A., Kraus, M.H., Bejar J. and Ron, D. (2007) Downregulation of Sef, an inhibitor of receptor tyrosine kinase signaling, is common to a vareity of human carcinomas. Oncogene 26, 6093-6098
- Fuchs Y., Brunwasser M., Haif S., Haddad J., Shneyer B., Goldshmidt-Tran O., Korsensky L., Abed M., Zisman-Rozen S., Koren L., Carmi Y., Apte R., Yang RB., Orian A., Bejar J. and Ron D. (2012) Sef Is an Inhibitor of Proinflammatory Cytokine Signaling, Acting by Cytoplasmic Sequestration of NF-κB. Developmental Cell 23, 611-23.
- Mishel S., Shneyer B., Korsensky l., Goldshmidt-Tran O., Haber T., Machluf M., and Ron D. (2017) Delivery of the gene encoding the tumor suppressor Sef into prostate tumors by therapeutic-ultrasound inhibits both tumor angiogenesis and growth. Sci. Reports, 7(1):15060
- Korsensky L, Haif S, Heller R, Rabinovitz S, Haddad-Halloun J, Dahan N., and Ron D. (2019) The tumor suppressor Sef is a scaffold for the classical NF-κB/RELA:P50 signaling module. Cell Signal. 59:110-121
1976 – BSc (cum laude), Biology Department, Ben-Gurion University of the Negev
1979– MSc (cum laude), Biology Department, Ben-Gurion University of the Negev
1984– PhD, Biology Department, Ben-Gurion University of the Negev
1984- 1987, Post-Doctoral fellow, National Cancer Institute, NIH, USA
1987 –1990, Visiting Associate, National Cancer Institute, NIH, USA
1990– Visiting Scientist, National Cancer Institute, NIH, USA